RecruitingNot applicableNCT03290456
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospices Civils de Lyon
- Principal Investigator
- Jean-Christophe LEGA, PrHospices Civils de Lyon
- Intervention
- Prednisone 5mg/day extended of 12 additional months(drug)
- Enrollment
- 146 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2029
Study locations (30)
- CHU Amiens-Hôpital Nord, Amiens, France
- CHU Angers, Angers, France
- Clinique Rhône-Durance, Avignon, France
- Hôpital Jeanne d'Arc, Bar-le-Duc, France
- Hôpital Avicenne, Bobigny, France
- Hôpital La Cavale Blanche, Brest, France
- Hôpital Louis Pradel, Bron, France
- CHU de Caen - Cote de Nacre, Caen, France
- Hôpital Louis Pasteur, Chartres, France
- CHU Estaing, Clermont-Ferrand, France
- CHU Gabriel Montpied, Clermont-Ferrand, France
- CHIC Créteil, Créteil, France
- CHRU François Mitterrand, Dijon, France
- CHRU Lille - Hôpital Claude Huriez, Lille, France
- Centre Hospitalier Croix Rousse, Lyon, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03290456 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →